201 related articles for article (PubMed ID: 12869079)
1. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
Shale MJ; Riley SA
Aliment Pharmacol Ther; 2003 Jul; 18(2):191-8. PubMed ID: 12869079
[TBL] [Abstract][Full Text] [Related]
2. Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds.
Shaw IS; Jobson BA; Silverman D; Ford J; Hearing SD; Ball D; Johnson E; Day A; Probert CS
Aliment Pharmacol Ther; 2002 Dec; 16(12):2053-9. PubMed ID: 12452937
[TBL] [Abstract][Full Text] [Related]
3. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
[TBL] [Abstract][Full Text] [Related]
4. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Hussain FN; Ajjan RA; Riley SA
Br J Clin Pharmacol; 2000 Apr; 49(4):323-30. PubMed ID: 10759687
[TBL] [Abstract][Full Text] [Related]
5. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Hussain FN; Ajjan RA; Kapur K; Moustafa M; Riley SA
Aliment Pharmacol Ther; 2001 Jan; 15(1):53-62. PubMed ID: 11136278
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: the use of mesalazine in inflammatory bowel disease.
Bergman R; Parkes M
Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
8. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
[TBL] [Abstract][Full Text] [Related]
9. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
Tebano MT; Traversa G; Da Cas R; Loizzo A
Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773
[TBL] [Abstract][Full Text] [Related]
10. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
11. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
Gionchetti P; Campieri M; Venturi A; Rizzello F; Ferretti M; Brignola C; Miglioli M
Aliment Pharmacol Ther; 1996 Aug; 10(4):601-5. PubMed ID: 8853765
[TBL] [Abstract][Full Text] [Related]
12. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
13. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse.
Robinson A; Hankins M; Wiseman G; Jones M
Aliment Pharmacol Ther; 2013 Sep; 38(5):531-8. PubMed ID: 23834298
[TBL] [Abstract][Full Text] [Related]
14. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease.
Carty E; MacEy M; Rampton DS
Aliment Pharmacol Ther; 2000 Sep; 14(9):1169-79. PubMed ID: 10971234
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
17. Nonadherence in inflammatory bowel disease: results of factor analysis.
Cervený P; Bortlík M; Kubena A; Vlcek J; Lakatos PL; Lukás M
Inflamm Bowel Dis; 2007 Oct; 13(10):1244-9. PubMed ID: 17538983
[TBL] [Abstract][Full Text] [Related]
18. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
19. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
20. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art.
Veloso PM; Machado R; Nobre C
Eur J Pharm Biopharm; 2021 Oct; 167():89-103. PubMed ID: 34329709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
